WVE (Wave Life Sciences Ltd) Company Net Income

Official company branding of wavelifesciences.com (WVE)

The Wave Life Sciences (WVE) profit chart demonstrates the financial results of the company, whose revenues are based on licensing royalties from pharma behemoths for the development of drugs against Duchenne muscular dystrophy and Huntington's disease. The current figure is -0.21. Leadership in genetics is driven by the PRISM DNA correction platform, however, significant clinical trial expenditures and the risk of research failure create serious pressure on capital.

WVE (Wave Pharma) Company Net Income history from 07/04/2022 to 10/30/2026

Financial and market metric breakdowns for Wave Life Sciences Ltd. (WVE)

- share price and consensus valuation forecast:
Price Chart Wave Pharma|WVE - Analyst Consensus Forecast
- business market valuation indicators:
Market Value Wave Pharma|WVE - Real Price to Acquire Entire Company
- balance sheet equity data:
Accounting Value of a Share Wave Life Sciences|WVE - Company Book Value|Market Value to Book Value Ratio wavelifesciences.com|WVE - Company Total Assets
- debt and solvency information:
Total Debt to Capital Coefficient Wave Life Sciences|WVE - Long-Term Debt to Capital|Current Liabilities to Equity Wave Life Sciences Ltd|WVE - Company Aggregate Debts|Debts to Book Value Wave Pharma|WVE - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Wave Life Sciences|Interim Coverage Ratio wavelifesciences.com
- net income and valuation multiples indicators:
WVE - Net Profit
Fundamental valuation:WVE Wave Pharma
Mass-produced product of wavelifesciences.com

The operational activities of Wave Life Sciences (WVE) are directly reflected in the dynamics of the company's net financial profit. This metric captures daily operating income, excluding market noise and emotional price fluctuations. The calculation allows for an assessment of real business efficiency through the prism of actual cash flows. For this RNA therapy developer, this indicator demonstrates resilience to economic cycles. The stability of these figures confirms the quality of assets while capital remains available for clinical trials.

Key competitors

TEM (Tempus AI) - Company Net Income|QGEN (Qiagen N.V.) - Net Profit|Company Net Income ionispharma.com IONS|Net Income RGEN (Repligen)|RNA (Avidity Biosciences Inc) - Final Profit|Company Net Income CRISPR Therapeutics Corp CRSP|GeneDx Corp - Company Net Income|Ultragenyx Pharmaceutical - Net Profit|Net Financial Result beamtx.com BEAM|SRPT: Net Profit|Profit After Tax TWST (Twist Bioscience Inc)|TXG (10x Genomics Corp) - Net Profit|Company Net Income Intellia Corp NTLA|Net Income STOK (Stoke Therapeutics)|BLFS (biolifesolutions.com) - Final Profit|Company Net Income Maze Therapeutics MAZE|Net Financial Result Sionna Therapeutics, Inc. (SION)|Prime Medicine Corp - Net Profit|Taysha Corp (TSHA) - Net Income|QURE: Net Profit|MGTX - Net Financial Result|RGNX (REGENXBIO) - Net Profit|Company Net Income Solid Biosciences Inc SLDB|Company Net Income Ocugen Corp (OCGN)|PacBio Corp - Company Profit|Net Profit BNTC (Benitec Biopharma Inc.)|DSGN - Net Income|Rocket Pharmaceuticals, Inc. - Net Profit|Company Net Income 4DMT|lexeotx.com (LXEO) - Company Net Income|KRRO - Net Financial Result|Net Income EDIT|Net Income silence-therapeutics.com (SLN)|Net Income PRQR (ProQR Therapeutics N.V.)|Company Net Income CDXS (codexis.com)|Net Profit SGMO (Sangamo)|Nautilus Biotechnology, Inc. (NAUT) - Company Net Income|Metagenomi, Inc. - Net Profit|DTIL (Precision BioSciences Inc.) - Company Profit|generationbio.com (GBIO) - Company Net Income|Company Profit BOLD|XCUR (Exicure Inc.) - Net Profit|Net Profit Celsion Corporation|Net Income PHIO (Phio Pharmaceuticals)|Net Income mustangbio.com MBIO|Net Profit RNAZ (TransCode Therapeutics, Inc.)|Net Profit Bionano Genomics Inc. BNGO|APDN: Net Income|BLUE: Company Net Income|IPA: Net Profit|Company Net Income omegatherapeutics.com (OMGA)|Net Income OMIC|RGLS: Final Profit|Company Net Income Syros (SYRS)|Company Net Income TBIO (Telesis Bio, Inc)|Net Profit TCON (TRACON Pharmaceuticals)|Net Financial Result unitybiotechnology.com (UBX)